Table 1.
Single dosage (n= 8) | ||||
Placebo | Memantine | |||
Before training | After training | Before training | After training | |
x coordinate COG (cm) | 1.58 ± 0.61 | 1.59 ± 0.67 | 1.43 ± 0.72 | 1.58 ± 0.62 |
y coordinate COG (cm) | -4.82 ± 0.44 | -4.74 ± 0.41 | -4.98 ± 0.56 | -4.97 ± 0.65 |
Motor threshold (%) | 34.6 ± 3.0 | 34.1 ± 2.7 | 35.0 ± 1.7 | 34.4 ± 1.9 |
Area (cm2) | 14.6 ± 4.4 | 13.8 ± 2.8 | 15.5 ± 5.2 | 16.1 ± 2.8 |
Sum of amplitudes (μV) | 1584.6 ± 999.6 | 1412.0 ± 797.8 | 2022.4 ± 1193.6 | 1733.0 ± 756.6 |
Number of "hotspots" | 3.4 ± 2.4 | 2.7 ± 2.6 | 4.2 ± 2.8 | 3.4 ± 2.3 |
Mean amplitude (μV) | 116.1 ± 94.9 | 100.4 ± 49.9 | 161.9 ± 180.6 | 111.4 ± 53.9 |
Ascending dosage over 8 days (n = 7) | ||||
Placebo | Memantine | |||
Before training | After training | Before training | After training | |
x coordinate COG (cm) | 1.21 ± 0.60 | 1.38 ± 0.59 | 1.49 ± 0.64 | 1.53 ± 0.66 |
y coordinate COG (cm) | -5.46 ± 0.69 | -5.34 ± 0.61 | -5.36 ± 0.50 | -5.44 ± 0.59 |
Motor threshold (%) | 40.6 ± 7.1 | 39.7 ± 6.5 | 41.3 ± 7.3 | 40.9 ± 7.0 |
Area (cm2) | 16.6 ± 3.8 | 15.7 ± 3.6 | 15.9 ± 3.6 | 16.3 ± 3.7 |
Sum of amplitudes (μV) | 1901.6 ± 1515.8 | 1535.1 ± 939.3 | 1744.4 ± 1086.0 | 1726.7 ± 808.6 |
Number of "hotspots" | 4.4 ± 3.5 | 3.6 ± 2.6 | 3.9 ± 3.1 | 3.6 ± 2.8 |
Mean amplitude (μV) | 120.5 ± 95.4 | 104.3 ± 65.0 | 107.2 ± 52.7 | 107.6 ± 45.2 |
Low dosage (10 mg/d) over 8 days (n = 5) | ||||
Memantine | ||||
Before training | After training | |||
x coordinate COG (cm) | 0.80 ± 0.46 | 0.62 ± 0.71 | ||
y coordinate COG (cm) | -5.12 ± 0.46 | -5.20 ± 0.53 | ||
Motor threshold (%) | 38.4 ± 8.3 | 38.8 ± 12.1 | ||
Area (cm2) | 12.0 ± 4.1 | 14.6 ± 4.0 | ||
Sum of amplitudes (μV) | 1852.2 ± 2169.4 | 1984.6 ± 1686.1 | ||
Number of "hotspots" | 3.8 ± 3.8 | 4.0 ± 4.3 | ||
Mean amplitude (μV) | 131.2 ± 106.1 | 122.0 ± 92.5 |